There is increasing scrutiny around how science is communicated to the public, but what is the relationship between how scientists report their findings and how media reports it to the public? A study published in PLOS Biology by Marcia Triunfol and Fabio Gouveia suggests that when authors of scientific papers omit the basic fact that a study was conducted in mice (and not in humans) from the article title, journalists reporting on the paper tend to do the same.
A new therapy prompts immune defense cells to swallow misshapen proteins, amyloid beta plaques and tau tangles, whose buildup is known to kill nearby brain cells as part of Alzheimer's disease, a new study shows.
Study published in PLoS Biology shows that Alzheimer disease experimental papers that omit mice from their titles are linked to more science news stories and gain greater visibility. The finding points to yet another type of spin in the reporting of biomedical research.
A team of neuroscientists are calling for greater support of neuroscience research in Africa to combat 'brain drain' following a long-term analysis of research outputs in the continent.
Diego Mastroeni of the NDRC teamed up Forest White and Douglas Lauffenburger, to explore how protein and signaling pathways change in patients with Alzheimer's disease. Their work creates a new model of disease progression, taking advantage of the heterogeneity that is inherent to human studies.
A new USC study not only sheds light on how the APOE4 gene may cause some of the pathologies associated with Alzheimer's disease, but also suggests a new treatment target that might help people who carry the APOE4 gene in early and late stages of the disease. USC researchers found that APOE4 is associated with the activation of an inflammatory protein that causes a breakdown in the blood-brain barrier which protects the brain.
In patients with mild cognitive impairment, taking lipophilic statins more than doubles their risk of developing dementia compared to those who do not take statins. According to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting, positron emission tomography (PET) scans of lipophilic statin users revealed a highly significant decline in metabolism in the area of the brain that is first impacted by Alzheimer's disease.
A novel PET radiotracer has been shown to effectively measure increases in brain tau--a distinguishing characteristic of Alzheimer's disease--before any symptoms of the disease are observed. With the potential to measure increases in tau over a long period of time, this tracer offers an important tool to assess the effectiveness of Alzheimer's disease treatments in clinical trials. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.
A new imaging technique has the potential to detect neurological disorders--such as Alzheimer's disease--at their earliest stages, enabling physicians to diagnose and treat patients more quickly. Termed super-resolution, the imaging methodology combines position emission tomography (PET) with an external motion tracking device to create highly detailed images of the brain. This research was presented at the Society of Nuclear Medicine and Molecular Imaging's 2021 Virtual Annual Meeting.
In addition to plaques that accumulate outside of nerve cells in the brain, Alzheimer's disease is also characterised by changes inside these cells. Researchers from the Cell Signalling research group at the Chair of Molecular Biochemistry at RUB, headed by Dr. Thorsten Müller, have been studying what exactly happens in these cells. They determined that various proteins and protein components accumulate in the cells, which also affect their functions.